India’s Dr. Reddy’s To Reduce Facilities In Foreign Countries
This article was originally published in PharmAsia News
Except for those in the United States, India's Dr. Reddy's Laboratories plans to close some of its locations around the world, including in China. The decision is the company's response to the global financial crisis. In addition to China, Dr. Reddy's plans to close its operations in Africa, the Middle East and the former countries of the Soviet Union. The Dr. Reddy reductions reflect an overall experience by the Indian pharmaceutical industry, which sees the regions as drains on their resources as their currencies decline in value, according to industry experts. (Click here for more
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.